(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Taiho Oncology, Inc.
M.D. Anderson Cancer Center
Cancer Research UK
Federal Research Institute of Pediatric Hematology, Oncology and Immunology